TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19927040
Drug: MenC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenC vaccine booster
Study: 15616045
Drug: Isovolemic hemodilution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isovolemic hemodilution (IH) performed with 500 mL; identical volume of hydroxyethyl starch administered.
Study: 11788629
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH (0.025 mg/kg per day)
Study: 11788629
Drug: Medium dose
Normalized name: TRIGLYCERIDES,MEDIUM CHAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium dose GH (0.05 mg/kg per day)
Study: 11788629
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH (0.1 mg/kg per day)
Study: 10430551
Drug: ET (fentanyl)
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ET (fentanyl) with 200 microA direct current applied for 30 min at hourly intervals
Study: 10430551
Drug: ET (fentanyl)
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ET (fentanyl) with 200 microA direct current applied for 30 min at 4-hourly intervals
Study: 10430551
Drug: Intravenous fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous fentanyl 75 microg infused over 30 min every 4 h
Study: 7560622
Drug: 12,500 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12,500 IU of unfractionated heparin given subcutaneously twice daily for 4 months
Study: 2245983
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg clotrimazole vaginal tablet (n = 33)
Study: 7430504
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg prednisone (single dose)
Study: 7430504
Drug: Three 50
Normalized name: THREE-LOBE SAGE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three 50 mg prednisone doses given at 6-hr intervals
Study: 6391933
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg fenclofenac per day
Study: 6391933
Drug: Gold in
Normalized name: AVOBENZONE 20.36 mg in 1 mL / OCTISALATE 50.9 mg in 1 mL / OCTOCRYLENE 20.36 mg in 1 mL TOPICAL LOTION [Australian Gold Instant Bronzer 15 sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gold in standard doses
Study: 30912735
Drug: Dark chocolate
Normalized name: Ensure Original Dark Chocolate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dark chocolate (100 g, 72% cocoa)
Study: 27068478
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered iron saccharate (200 mg, two applications)
Study: 27068478
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered iron polymaltose complex (100 mg, twice a day for 8 weeks)
Study: 27068478
Drug: Intravenously administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenously administered iron saccharate
Study: 27068478
Drug: Orally administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orally administered iron polymaltose complex
Study: 24846620
Drug: TelePain intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TelePain intervention (report of symptoms and receipt of a pain graph) weekly for 8 weeks
Study: 22420597
Drug: quetiapine (25-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: quetiapine (25-300 mg, flexibly dosed)
Study: 15939920
Drug: Cisplatin 70
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 70 mg/qm(2) on day 1 and methotrexate 40 mg/qm(2) on days 8 and 15 of a 21-day cycle (CM)
Study: 15939920
Drug: Methotrexate 30
Normalized name: METHOTREXATE 30MG/0.6ML AUTO INJECTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 30 mg/qm(2) on days 1, 15, and 22, vinblastine 3 mg/qm(2) on days 2, 15, and 22, epirubicin 45 mg/qm(2) on day 2, and cisplatin 70 mg/qm(2) on day 2 of a 28-day cycle (M-VEC)
Study: 12424822
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of neuroleptic treatment
Study: 10325444
Drug: Silymarin (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (420 mg/day) + Tacrine (40 mg/day for 6 weeks, then increased to 80 mg/day for 6 weeks)
Study: 27829371
Drug: Consolidation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation therapy
Study: 2955799
Drug: Orgotein (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orgotein (4 or 8 mg)
Study: 23650901
Drug: Patch pump
Normalized name: subcut bolus insulin patch pump,200 unit,disposabl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch pump (PP)
Study: 19781874
Drug: Related agents
Normalized name: HORMONES AND RELATED AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Related agents
Study: 30123511
Drug: Early goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early goal-directed therapy (EGDT)
Study: 18159013
Drug: Conventional empirical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional empirical therapy (Control)
Study: 15321022
Drug: Grid laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grid laser photocoagulation and 0.5 mL of 40 mg/mL posterior subtenon triamcinolone
Study: 12646340
Drug: pravastatin 20
Normalized name: pravastatin 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: pravastatin 20 mg
Study: 2330116
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of levodopa and carbidopa
Study: 7408140
Drug: Dipyridamole (Persantine)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole (Persantine) and aspirin
Study: 20339615
Drug: DTPw-HepB-Hib fully
Normalized name: poliovirus vaccine inactivated, type 1 (Mahoney)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-HepB-Hib fully liquid vaccine
Study: 20339615
Drug: DTPw and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw and Hib vaccines administered separately
Study: 1894496
Drug: Active PEMF
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active PEMF therapy (pulsed electromagnetic fields)
Study: 1894496
Drug: Inactive PEMF
Normalized name: Pemfexy
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inactive PEMF therapy (control)
Study: 6361788
Drug: Suprofen 400
Normalized name: Suprofen
DrugBank: Suprofen (DB00870)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suprofen 400 mg
Study: 6361794
Drug: Diflunisal 750
Normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diflunisal 750 mg
Study: 30569790
Drug: Caffeine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3 mg·kg‐1 of body mass)
Study: 30569790
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 mg·kg‐1 of body mass of dextrose)
Study: 22465901
Drug: Wellmune (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wellmune (250 mg once daily)
Study: 15912413
Drug: Tenoxicam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (20 mg)
Study: 9895080
Drug: remifentanil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: remifentanil (all doses)
Study: 7735336
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + Arginine (0.5 g/kg infused over 30 min)
Study: 7735336
Drug: GHRH +
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH + Pyridostigmine (120 mg orally at -60 min)
Study: 3002577
Drug: Lumpectomy (L)
Normalized name: L-377202
DrugBank: L-377202 (DB19022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumpectomy (L)
Study: 29150790
Drug: Yishen Qufeng
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Yishen Qufeng Shengshi Recipe (YQSR), 200 mL, twice per day, orally for 6 months
Study: 29150790
Drug: Losartan, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan, 50 mg/d orally for 6 months
Study: 26506579
Drug: Family-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-Based Treatment for Adolescent Bulimia Nervosa (FBT-BN)
Study: 26506579
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy adapted for adolescents (CBT-A)
Study: 23372142
Drug: Calcium channel
Normalized name: Calcium channel blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium channel blockade (CCB) - 60 mg oral nimodipine
Study: 16646722
Drug: Verum acupuncture
Normalized name: Cinnamomum verum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verum acupuncture based on Traditional Chinese Medicine (TCM)
Study: 14656278
Drug: Single-agent chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent chemotherapy (carboplatin or new drug)
Study: 14656278
Drug: Platinum combination-based
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum combination-based therapy
Study: 11505405
Drug: Single-agent carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single-agent carboplatin
Study: 14656278
Drug: Single-agent new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent new drug
Study: 11025952
Drug: Amrinone infusion
Normalized name: AMRINONE
DrugBank: Amrinone (DB01427)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amrinone infusion (17 patients)
Study: 11025952
Drug: Milrinone infusion
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Milrinone infusion (15 patients)
Study: 11025952
Drug: Olprinone infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olprinone infusion (14 patients)
Study: 16306858
Drug: THC (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (10 mg)
Study: 16306858
Drug: Cannabis extract
Normalized name: Cannabis sativa whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cannabis extract (10 mg THC + 5.4 mg CBD)
Study: 1090905
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no group therapy)
Study: 9140674
Drug: Nicardipine SR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine SR (40‐80 mg for 21 months)
Study: 9140674
Drug: Alacepril (25‐100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alacepril (25‐100 mg for 18 months)
Study: 15538131
Drug: S-adenosyl-L-methionine
Normalized name: S-Adenosyl-L-Methionine (Sam-E)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine
Study: 30685685
Drug: Three-drug combination
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combination chemotherapy with methotrexate, doxorubicin, and cisplatin (standard chemotherapy)
Study: 25851756
Drug: Weekly azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly azathioprine 300 mg pulse
Study: 25851756
Drug: Daily azathioprine
Normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Daily azathioprine 100 mg
Study: 19318695
Drug: Intravenous tezosentan
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tezosentan at 0.2 mg/h for 24 hours followed by 1.0 mg/h for 24 hours (cohort I)
Study: 19318695
Drug: Intravenous tezosentan
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tezosentan at 1.0 mg/h for 24 hours followed by 5.0 mg/h for 24 hours (cohort II)
Study: 19318695
Drug: Intravenous tezosentan
Normalized name: TEZOSENTAN
DrugBank: Tezosentan (DB06558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tezosentan (cohort III)
Study: 15576069
Drug: Combined metyrapone/low‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined metyrapone/low‐dose dexamethasone test
Study: 8066866
Drug: n‐3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 PUFA capsules (3.6 g)
Study: 8066866
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (six capsules with a fat composition averaging the Danish diet)
Study: 28982497
Drug: Aspirin and
Normalized name: Aspirin and Caffeine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin and clopidogrel treatment for one year
Study: 9787686
Drug: RSV‐IGIV, 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV‐IGIV, 750 mg/kg, monthly
Study: 7664857
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 1 mg daily
Study: 7664857
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 2 mg daily
Study: 7664857
Drug: Budesonide, 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide, 1.6 mg daily
Study: 2523772
Drug: nimesulide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nimesulide (100 mg x 2/day)
Study: 2523772
Drug: phenylprenazone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylprenazone (200 mg x 2/day)
Study: 1820675
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no injection)
Study: 21277410
Drug: trivalent recombinant
Normalized name: INFLUENZA VACCINE,TRIVALENT RECOMBINANT (PF),VIL,0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: trivalent recombinant hemagglutinin (rHA) vaccine, 45 μg HA/strain
Study: 21277410
Drug: U.S. licensed
Approvals — FDA: no, EMA: no, PMDA: no
Description: U.S. licensed trivalent inactivated vaccine (TIV), 15 μg HA/strain
Study: 21277410
Drug: trivalent recombinant
Normalized name: INFLUENZA VACCINE,TRIVALENT RECOMBINANT (PF),VIL,0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: trivalent recombinant hemagglutinin (rHA) vaccine
Study: 18077012
Drug: 0.5 g
Normalized name: Gelatin Capsules, 10.5 gr
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 g Vit-C/day
Study: 18077012
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g Vit-C/day
Study: 16452740
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate (1 mL of 10 mg/mL)
Study: 16452740
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution (1 mL of phosphate-buffered saline)
Study: 30348219
Drug: Reading newspapers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reading newspapers daily or infrequently
Study: 27665206
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist treatment (e.g., warfarin)
Study: 27665206
Drug: Hemoglobin >13.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin >13.5 g/dl
Study: 24642648
Drug: Vaginal lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal lactoferrin (LF) 300 mg administered 4 hours before amniocentesis
Study: 24642648
Drug: Vaginal lactoferrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal lactoferrin (LF) 300 mg administered 12 hours before amniocentesis
Study: 16267768
Drug: Single-dose sulfadoxine-pyrimethamine
Normalized name: pyrimethamine / sulfadoxine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sulfadoxine-pyrimethamine (S-P)
Study: 17460371
Drug: losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: losartan 50 mg/day
Study: 7756640
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antithymocyte globulin (ATG) and cyclosporine (CsA) administered simultaneously for 4 days and 6 months respectively
Study: 2147837
Drug: Enoximone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (1 mg/kg bolus followed by intravenous infusion of 5 to 10 micrograms/Kg/mn)
Study: 29037641
Drug: Sham therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham therapy (SG)
Study: 26527536
Drug: Aqueous extract
Normalized name: green tea aqueous extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous extract of noble kava cultivar (standardised to 240 mg of kavalactones per day)
Study: 23098762
Drug: onabotulinumtoxinA (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: onabotulinumtoxinA (all doses)
Study: 10571630
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel at 4 degrees C
Study: 10571630
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel at 40 degrees C
Study: 10571630
Drug: 2% lignocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% lignocaine hydrochloride gel at 22 degrees C (control group)
Study: 6352001
Drug: Initial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial therapy directed at the poor-prognosis component of tumors
Study: 28767271
Drug: TEAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEAS plus exercise therapy (TG)
Study: 28767271
Drug: Sham TEAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham TEAS plus exercise therapy (CG)
Study: 26814294
Drug: ABT-639 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-639 (100 mg)
Study: 31992495
Drug: Pregabalin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (300 mg)
Study: 28657703
Drug: Oral rinse
Normalized name: Oral Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse
Study: 17421001
Drug: Whole-saliva and
Normalized name: Betula lenta whole
DrugBank: Betula lenta whole (DB14164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-saliva and oral-rinse samples
Study: 7896982
Drug: Brief psychodynamic-interpersonal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Brief psychodynamic-interpersonal treatment
Study: 7610222
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment
Study: 582549
Drug: Lithium medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium medication (dosage: 24 mval/d to 36 mval/d)
Study: 28397569
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (FLU‐IVIG)
Study: 28397569
Drug: Collapsing categories
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collapsing categories with no treatment effect
Study: 16877719
Drug: Arm 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arm 1: Bolus FU in two 5-day cycles every 28 days before and after radiotherapy plus FU via protracted venous infusion (PVI) 225 mg/m2/d during XRT
Study: 10971308
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg PSC (valspodar) as an i.v. infusion over 2 h
Study: 10971308
Drug: Morphine HCl
Normalized name: morphine HCl
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine HCl (7.5 mg) infused over 2 h
Study: 22370314
Drug: Gemcitabine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine and Cisplatin (GP) chemotherapy (gemcitabine 1,250 mg/m2 on days 1 and 8; cisplatin 80 mg/m2 on day 1 every 3 weeks, for up to nine courses)
Study: 12100939
Drug: Lanolin hand
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin hand cream
Study: 9137929
Drug: Carbimazole +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbimazole + Propranolol (40 mg)
Study: 3298419
Drug: Pre-trial dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-trial dosage of cis(z)‐flupenthixol decanoate
Study: 27209291
Drug: Oral lusutrombopag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lusutrombopag (14-day once-daily dosing)
Study: 27209291
Drug: Oral lusutrombopag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lusutrombopag
Study: 25311610
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg resveratrol capsule
Study: 23602776
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice-daily
Study: 23602776
Drug: Rivaroxaban 5
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban 5 mg twice-daily
Study: 16636364
Drug: Horsechestnut seed
Normalized name: Plantago Seed
DrugBank: Plantago seed (DB11097)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Horsechestnut seed extract therapy combined with conventional therapy
Study: 10977025
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment with insulin alone or with sulfonylurea (n = 75)
Study: 10977025
Drug: Standard once-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard once-daily insulin injection (n = 78)
Study: 10977025
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (n = 66)
Study: 10977025
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (n = 70)
Study: 8841900
Drug: Systemic tetracycline
Normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic tetracycline (250 mg qds for 14 days)
Study: 8841900
Drug: Modified Widman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Widman flap surgery with adjunctive tetracycline
Study: 29695594
Drug: Ofatumumab 3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab 3, 30, or 60 mg every 12 weeks, or 60 mg every 4 weeks
Study: 18390837
Drug: Ofatumumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofatumumab (all doses)
Study: 25004803
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) (Control Group, CG) for 5 weeks
Study: 22872468
Drug: Oral peptone
Normalized name: peptones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral peptone load (10 g)